A clinical trial involving GHK-Cu was registered as of July 15, 2026. The study, titled "Two-Part Study of the Effects of the X39 Patch on Circulating GHK and GHK-Cu Levels in Healthy Adults," is listed under identifier NCT07706361.
The trial has a phase designation of NA and a current status of not yet recruiting. This means participant enrollment has not yet begun.
According to the registration data, the study is designed to look at circulating levels of GHK and GHK-Cu in healthy adults following use of the X39 patch. No results, outcomes, or findings have been posted for this trial at this time.
As a two-part study, the design suggests multiple phases of data collection, though specific structural details beyond the title are not included in the current registration.
Because the trial is not yet recruiting, no participant data, safety information, or efficacy signals are currently available. The registration represents the formal listing of the study's intent and scope on ClinicalTrials.gov.
Updates to status, recruitment, and any eventual results would be reflected in future changes to this trial's record under the same identifier.
Readers interested in background information on this compound can consult the compound overview for additional context.